camizestrant · Astrazeneca · NDA 220359
Etcamah
Earliest generic entry, as listed
22 Oct 2041
Blocked by patent: US 12453729.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12453729 | drug product · sets the listed date | 22 Oct 2041 |
| US 12364689 | use U-4606 | 18 Sep 2041 |
| US 10131663 | drug substance, drug product | 13 Oct 2037 |
| US 10590130 | drug substance, drug product | 13 Oct 2037 |
| US 10961241 | use U-4607 | 13 Oct 2037 |
| US 12077530 | use U-4607 | 13 Oct 2037 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 4 Sep 2031 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 220359 · 001 · RLD | tablet, oral | 75MG | 22 Oct 2041 |